Skip to main content
Erschienen in: Die Kardiologie 6/2023

24.10.2023 | Anthrazykline | CME

Update Kardioonkologie: Anthrazyklin-Chemotherapie

verfasst von: Dr. med. Lars Michel, Prof. Dr. med. Tienush Rassaf

Erschienen in: Die Kardiologie | Ausgabe 6/2023

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Kardioonkologie ist ein integraler Bestandteil der Behandlung von Patientinnen und Patienten mit Krebserkrankung. Durch die verbesserte Langzeitprognose, das komplexe Spektrum onkologischer Therapien und kardiovaskulärer Komorbiditäten gewinnt die bestmögliche Prävention, Diagnostik und Behandlung von Krebstherapie-assoziierten kardiovaskulären Nebenwirkungen weiter an Bedeutung. Im Folgenden werden Strategien zur Überwachung, geeignete diagnostische Modalitäten und Therapieoptionen am Beispiel der Anthrazyklin-Chemotherapie zusammengefasst. Ein besonderer Fokus liegt auf der bestmöglichen medikamentösen Therapie sowie auf den positiven Auswirkungen einer sportlichen Betätigung zur Prävention einer Anthrazyklin-assoziierten kardiovaskulären Nebenwirkung.
Literatur
1.
Zurück zum Zitat Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. https://doi.org/10.1093/eurheartj/ehac244CrossRefPubMed Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. https://​doi.​org/​10.​1093/​eurheartj/​ehac244CrossRefPubMed
2.
Zurück zum Zitat Rassaf T, Totzeck M, Backs J, Bokemeyer C, Hallek M, Hilfiker-Kleiner D, Hochhaus A, Lüftner D, Müller OJ, Neudorf U, Pfister R, von Haehling S, Lehmann LH, Bauersachs J (2020) Onco-cardiology: consensus paper of the German cardiac society, the German society for pediatric cardiology and congenital heart defects and the German society for hematology and medical oncology. Clin Res Cardiol 109(10):1197–1222. https://doi.org/10.1007/s00392-020-01636-7CrossRefPubMedPubMedCentral Rassaf T, Totzeck M, Backs J, Bokemeyer C, Hallek M, Hilfiker-Kleiner D, Hochhaus A, Lüftner D, Müller OJ, Neudorf U, Pfister R, von Haehling S, Lehmann LH, Bauersachs J (2020) Onco-cardiology: consensus paper of the German cardiac society, the German society for pediatric cardiology and congenital heart defects and the German society for hematology and medical oncology. Clin Res Cardiol 109(10):1197–1222. https://​doi.​org/​10.​1007/​s00392-020-01636-7CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, López-Fernández T, Plummer C, Lenihan D (2020) Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 22(11):1945–1960. https://doi.org/10.1002/ejhf.1920CrossRefPubMed Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, López-Fernández T, Plummer C, Lenihan D (2020) Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 22(11):1945–1960. https://​doi.​org/​10.​1002/​ejhf.​1920CrossRefPubMed
7.
Zurück zum Zitat Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229–4361. https://doi.org/10.1093/eurheartj/ehac244CrossRefPubMed Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229–4361. https://​doi.​org/​10.​1093/​eurheartj/​ehac244CrossRefPubMed
8.
Zurück zum Zitat Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37(36):2768–2801. https://doi.org/10.1093/eurheartj/ehw211CrossRefPubMed Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37(36):2768–2801. https://​doi.​org/​10.​1093/​eurheartj/​ehw211CrossRefPubMed
10.
Zurück zum Zitat Haddy N, Diallo S, El-Fayech C, Schwartz B, Pein F, Hawkins M, Veres C, Oberlin O, Guibout C, Pacquement H, Munzer M, N’Guyen TD, Bondiau PY, Berchery D, Laprie A, Scarabin PY, Jouven X, Bridier A, Koscielny S, Deutsch E, Diallo I, de Vathaire F (2016) Cardiac diseases following childhood cancer treatment: cohort study. Circulation 133(1):31–38. https://doi.org/10.1161/circulationaha.115.016686CrossRefPubMed Haddy N, Diallo S, El-Fayech C, Schwartz B, Pein F, Hawkins M, Veres C, Oberlin O, Guibout C, Pacquement H, Munzer M, N’Guyen TD, Bondiau PY, Berchery D, Laprie A, Scarabin PY, Jouven X, Bridier A, Koscielny S, Deutsch E, Diallo I, de Vathaire F (2016) Cardiac diseases following childhood cancer treatment: cohort study. Circulation 133(1):31–38. https://​doi.​org/​10.​1161/​circulationaha.​115.​016686CrossRefPubMed
11.
Zurück zum Zitat McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli FM, Price S, Rosano GMC, Ruschitzka F, Skibelund KA (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368CrossRefPubMed McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli FM, Price S, Rosano GMC, Ruschitzka F, Skibelund KA (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726. https://​doi.​org/​10.​1093/​eurheartj/​ehab368CrossRefPubMed
12.
13.
Zurück zum Zitat Lenčová-Popelová O, Jirkovský E, Jansová H, Jirkovská-Vávrová A, Vostatková-Tichotová L, Mazurová Y, Adamcová M, Chládek J, Hroch M, Pokorná Z, Geršl V, Šimůnek T, Štěrba M (2016) Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: comparison with dexrazoxane. J Mol Cell Cardiol 91:92–103. https://doi.org/10.1016/j.yjmcc.2015.12.021CrossRefPubMed Lenčová-Popelová O, Jirkovský E, Jansová H, Jirkovská-Vávrová A, Vostatková-Tichotová L, Mazurová Y, Adamcová M, Chládek J, Hroch M, Pokorná Z, Geršl V, Šimůnek T, Štěrba M (2016) Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: comparison with dexrazoxane. J Mol Cell Cardiol 91:92–103. https://​doi.​org/​10.​1016/​j.​yjmcc.​2015.​12.​021CrossRefPubMed
14.
15.
Zurück zum Zitat Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK, Smith A, Heemelaar JC, Brahmbhatt P, Ho JS, Sama S, Svoboda J, Neuberg DS, Abramson JS, Hochberg EP, Barnes JA, Armand P, Jacobsen ED, Jacobson CA, Kim AI, Soumerai JD, Han Y, Friedman RS, Lacasce AS, Ky B, Landsburg D, Nasta S, Kwong RY, Jerosch-Herold M, Redd RA, Hua L, Januzzi JL, Asnani A, Mousavi N, Scherrer-Crosbie M (2023) Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial. JAMA 330(6):528–536. https://doi.org/10.1001/jama.2023.11887CrossRefPubMed Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK, Smith A, Heemelaar JC, Brahmbhatt P, Ho JS, Sama S, Svoboda J, Neuberg DS, Abramson JS, Hochberg EP, Barnes JA, Armand P, Jacobsen ED, Jacobson CA, Kim AI, Soumerai JD, Han Y, Friedman RS, Lacasce AS, Ky B, Landsburg D, Nasta S, Kwong RY, Jerosch-Herold M, Redd RA, Hua L, Januzzi JL, Asnani A, Mousavi N, Scherrer-Crosbie M (2023) Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial. JAMA 330(6):528–536. https://​doi.​org/​10.​1001/​jama.​2023.​11887CrossRefPubMed
16.
Zurück zum Zitat Thavendiranathan P, Houbois C, Marwick TH, Kei T, Saha S, Runeckles K, Huang F, Shalmon T, Thorpe KE, Pezo RC, Prica A, Maze D, Abdel-Qadir H, Connelly K, Chan J, Billia F, Power C, Hanneman K, Wintersperger BJ, Brezden-Masley C, Amir E (2023) Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Eur Heart J Cardiovasc Pharmacother. https://doi.org/10.1093/ehjcvp/pvad031CrossRefPubMed Thavendiranathan P, Houbois C, Marwick TH, Kei T, Saha S, Runeckles K, Huang F, Shalmon T, Thorpe KE, Pezo RC, Prica A, Maze D, Abdel-Qadir H, Connelly K, Chan J, Billia F, Power C, Hanneman K, Wintersperger BJ, Brezden-Masley C, Amir E (2023) Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Eur Heart J Cardiovasc Pharmacother. https://​doi.​org/​10.​1093/​ehjcvp/​pvad031CrossRefPubMed
17.
Zurück zum Zitat Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, Collet JP, Corrado D, Drezner JA, Halle M, Hansen D, Heidbuchel H, Myers J, Niebauer J, Papadakis M, Piepoli MF, Prescott E, Roos-Hesselink JW, Stuart GA, Taylor RS, Thompson PD, Tiberi M, Vanhees L, Wilhelm M (2021) 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 42(1):17–96. https://doi.org/10.1093/eurheartj/ehaa605CrossRefPubMed Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, Collet JP, Corrado D, Drezner JA, Halle M, Hansen D, Heidbuchel H, Myers J, Niebauer J, Papadakis M, Piepoli MF, Prescott E, Roos-Hesselink JW, Stuart GA, Taylor RS, Thompson PD, Tiberi M, Vanhees L, Wilhelm M (2021) 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 42(1):17–96. https://​doi.​org/​10.​1093/​eurheartj/​ehaa605CrossRefPubMed
18.
Zurück zum Zitat Foulkes SJ, Howden EJ, Haykowsky MJ, Antill Y, Salim A, Nightingale SS, Loi S, Claus P, Janssens K, Mitchell AM, Wright L, Costello BT, Lindqvist A, Burnham L, Wallace I, Daly RM, Fraser SF, La Gerche A (2023) Exercise for the prevention of anthracycline-induced functional disability and cardiac dysfunction: the BREXIT study. Circulation 147(7):532–545. https://doi.org/10.1161/circulationaha.122.062814CrossRefPubMed Foulkes SJ, Howden EJ, Haykowsky MJ, Antill Y, Salim A, Nightingale SS, Loi S, Claus P, Janssens K, Mitchell AM, Wright L, Costello BT, Lindqvist A, Burnham L, Wallace I, Daly RM, Fraser SF, La Gerche A (2023) Exercise for the prevention of anthracycline-induced functional disability and cardiac dysfunction: the BREXIT study. Circulation 147(7):532–545. https://​doi.​org/​10.​1161/​circulationaha.​122.​062814CrossRefPubMed
20.
Zurück zum Zitat Antunes P, Joaquim A, Sampaio F, Nunes C, Ascensão A, Vilela E, Teixiera M, Capela A, Amarelo A, Marques C, Viamonte S, Alves A, Esteves D (2023) Effects of exercise training on cardiac toxicity markers in women with breast cancer undergoing chemotherapy with anthracycline: a randomized controlled trial. Eur J Prev Cardiol. https://doi.org/10.1093/eurjpc/zwad063CrossRefPubMed Antunes P, Joaquim A, Sampaio F, Nunes C, Ascensão A, Vilela E, Teixiera M, Capela A, Amarelo A, Marques C, Viamonte S, Alves A, Esteves D (2023) Effects of exercise training on cardiac toxicity markers in women with breast cancer undergoing chemotherapy with anthracycline: a randomized controlled trial. Eur J Prev Cardiol. https://​doi.​org/​10.​1093/​eurjpc/​zwad063CrossRefPubMed
21.
Metadaten
Titel
Update Kardioonkologie: Anthrazyklin-Chemotherapie
verfasst von
Dr. med. Lars Michel
Prof. Dr. med. Tienush Rassaf
Publikationsdatum
24.10.2023
Verlag
Springer Medizin
Erschienen in
Die Kardiologie / Ausgabe 6/2023
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI
https://doi.org/10.1007/s12181-023-00638-9

Weitere Artikel der Ausgabe 6/2023

Die Kardiologie 6/2023 Zur Ausgabe